Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Stocks Stunted Midday as Reopening Plays Weaken ↗
The major indexes have pared most of their pre-market gains, giving way to a somewhat static afternoon. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's... 
Via Benzinga
What's Going On With Pieris Pharmaceuticals Stock Today? ↗
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are tradin... 
Via Benzinga
News headline image
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings ↗
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) shares increased by 27.99% to $5.99 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
News headline image
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
- Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs -... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
News headline image
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
News headline image
Pieris Pharmaceuticals: Q1 Earnings Insights ↗
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past... 
Via Benzinga
News headline image
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT - PRS-060/AZD1402 dosed to first patient in phase 2a study - Cinrebafusp alfa (PRS-343) phase 2 study expected to... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
News headline image
Earnings Scheduled For May 17, 2021 ↗
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off ↗
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
News headline image
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off ↗
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
News headline image
Earnings Preview: Pieris Pharmaceuticals ↗
On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release... 
Via Benzinga
News headline image
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties - Boston Pharmaceuticals will be primarily responsible for development of the... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers 180 Life Sciences (NASDAQ:ATNF) shares increased by 27.31% to $12.4 during Monday's regular session. Trading volume for 180 Life Sciences's stock is 29.3... 
Via Benzinga
News headline image
42 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
News headline image
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
- Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa - Durable anti-tumor activity... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.